Gilead Sciences: Why Cancer Drug Licensing is a Good Start

RBC’s Michael Yee likes Gilead Sciences (GILD) decision to license Ono’s early-stage oral-cancer drug. He explains why: Associated Press We are positive on the Gilead in-licensing of ONO’s Phase I BTK oral cancer drug. This drug is very “similar” to Pharmacyclics’ (PCYC) ibrutinib ($5-6B consensus peak sales), and has similarly high response rates and clean [...]